Table 1.
GOG Studies stratified by tumor site
| Ovary | Endometrial | Cervix | Sarcoma | Totals | |
|---|---|---|---|---|---|
| Number of studies | 202 (45%) | 70 (16%) | 128 (29%) | 45 (10%) | 445 (100%) |
| Number of patients | 35,800 (57%) | 14,516 (21%) | 14,848 (22%) | 2,404 (4%) | 67,568 (100%) |
| Type of Study | |||||
| Phase I | 28 (13.9%) | 4 (5.8%) | 11 (8.6%) | 0 (0%) | 43 (9.7%) |
| Phase II | 118 (58.4%) | 49 (70%) | 83 (64.8%) | 40 (88.9%) | 290 (65%) |
| Phase III | 36 (17.8%) | 13 (18.6%) | 26 (20.3%) | 5 (11.1%) | 80 (18%) |
| Observational | 12 (5.9%) | 0 (0%) | 6 (4.7%) | 0 (0%) | 18 (4%) |
| Translational | 8 (3.9%) | 3 (4.3%) | 2 (1.6%) | 0 (0%) | 13 (2.9%) |
| Publication Years | |||||
| ≤ 1993 | 43 (21.3%) | 13 (18.6%) | 46 (35.9%) | 11 (24.4%) | 113 (25.4%) |
| 1994 to 2002 | 44 (21.8%) | 15 (21.4%) | 42 (32.8%) | 16 (35.6%) | 117 (26.3%) |
| 2003 to 2008 | 45 (22.3%) | 25 (35.7%) | 27 (21.1%) | 11 (24.4%) | 108 (24.3%) |
| 2009 to 2013 | 70 (34.7%) | 17 (24.3%) | 13 (10.2%) | 7 (15.6%) | 107 (24%) |